Alixia was founded by Olof Mollstedt, Helen Chen in 2022.

Who are Alixia's investors?

Alixia's investors include Eight Capital, Gaingels, StartX, Y Combinator, ZAKA VC, AJG, GoodFin Ventures, SOSV.

How much funding has Alixia raised?

Alixia has disclosed $1.8M raised across 1 round.

Where is Alixia headquartered?

Alixia is headquartered in San Francisco, US.

Alixia

YC W22

San Francisco, US · Founded 2022 · Delaware corporation · 2 employees · 8 known investors

Find your way into Alixia

Paths you didn't know you had: your email and LinkedIn already hold routes to the Alixia team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

Also known as Guided Clarity

Biotech Deep Tech Healthtech Medical Devices Therapeutics Drug discovery Oncology BiotechnologyUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W22)

Alixia was founded in 2022 by Olof Mollstedt and Helen Chen.

Olof MollstedtCo-Founder

Helen Chen Co-FounderHelen Chen is a researcher with expertise in cancer and aging biology who is now building Alixia.

Board

Sungwon LimBoard director

Investors · 8

Eight Capitallisted by Eight CapitalNorwalk

How we know: Y Combinator's founder network · eightcapital.com · Not right? Tell us

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: Y Combinator's founder network · gaingels.com · Not right? Tell us

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

ZAKA VClisted by ZAKA VCSan Francisco

AJGreported

How we know: Y Combinator's founder network · Not right? Tell us

GoodFin Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

SOSVreportedNew York · $30K – $550K

How we know: Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$1.8M disclosed across 1 round · 2024

▶$1.8MraisedJul 2024 · 19 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Sungwon LimDirector
Lars Olof MollstedtExecutive Officer, Director
Helen Yee-Fang ChenExecutive Officer, Director

Offering amount: $3.5M
Amount sold: $1.8M
First sale: Jul 2024
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 10

Antheia, Inc.Antheia uses a yeast-based biosynthesis and fermentation platform to manufacture Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines, offering an alternative to fragile agricultural sourcing. The company targets pharmaceutical supply chains, aiming to reduce drug shortages and improve reliability for medicines traditionally derived from plants.

Eugit TherapeuticsTissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

Adventris PharmaceuticalsAdventris is a biotechnology company developing cancer immunotherapy treatments.

Areteia TherapeuticsAreteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

Velorum TherapeuticsVelorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.

Eris BiotechEris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.

Notable LabsNotable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.

Lycia TherapeuticsLycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Intellia TherapeuticsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

Companies working in the same space as Alixia.

Legal entities · 1

corporate structure

Alixia, Inc.

Frequently asked questions

What does Alixia do?: Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.
Who founded Alixia?: Alixia was founded by Olof Mollstedt, Helen Chen in 2022.
Who are Alixia's investors?: Alixia's investors include Eight Capital, Gaingels, StartX, Y Combinator, ZAKA VC, AJG, GoodFin Ventures, SOSV.
How much funding has Alixia raised?: Alixia has disclosed $1.8M raised across 1 round.
Where is Alixia headquartered?: Alixia is headquartered in San Francisco, US.